AGL

Across TCGA pan-cancer cohorts, AGL Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated AGL data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher AGL Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated AGL expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

LUSC, BRCA, and OV are the cancer types where AGL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.079	0.792	<.001	28	view →
BRCA	OS	Median	III,IV	0.157	0.906	<.001	24	view →
OV	DFS	Median	All	0.300	0.542	.041	18	view →
DLBC	OS	Median	All	0.054	0.842	<.001	12	view →
LIHC	DFS	Median	All	0.080	0.553	.004	12	view →
BLCA	DFS	Median	All	0.772	0.316	.008	12	view →
UCEC	DFS	Median	All	0.913	0.600	.009	12	view →
PAAD	OS	Median	All	0.131	0.640	.012	6	view →
KIRP	DFS	Median	All	0.218	0.771	.029	6	view →
PRAD	DFS	Median	All	0.085	0.774	.003	6	view →
HNSC	OS	Median	All	0.476	0.771	.022	3	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

AGL–LUSC (DFS)

Open the LUSC breakdown →